Stocks
Pfenex IncPFNX
HealthcareBiotechnology
A specialty pharmaceutical company focused on developing and commercializing complex generic and biosimilar versions of biologic drugs. Its lead product, a generic version of Neupogen (filgrastim), received FDA approval in 2018, and the company has a pipeline targeting other difficult-to-manufacture biologics. Investors track Pfenex for its regulatory milestones and potential market share gains in the biosimilar space.
Congressional Interest in Pfenex Inc (PFNX)
1 member of Congress has disclosed 1 trade in Pfenex Inc (PFNX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading PFNX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-01-15 | MICHAEL T. MCCAUL | buy | $1K-$15K |